Year: 2026
Type: article
Abstract: Thyroid eye disease (TED), also known as Graves’ ophthalmopathy or thyroid-associated orbitopathy (TAO), is the most common cause of both unilateral and bilateral proptosis in adults. It is an autoimmune inflammatory disorder affecting the periorbital and orbital tissues, leading to a wide spectrum of heterogeneous clinical manifestations that can significantly impair quality of life and, in severe cases, threaten vision. The medical management of TED has evolved considerably over the past decade. Systemic corticosteroids remain the first-line therapy for controlling active inflammation. However, the landmark approval of teprotumumab—a human monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R)—by the U.S. Food and Drug Administration (FDA) in 2020 has transformed the therapeutic landscape. This advancement has ushered in a new era of targeted therapy for TED. This review summarizes the pathophysiology and clinical activity of TED and outlines a comprehensive framework for its medical management, encompassing both conventional treatments and emerging therapeutic approaches. J. Natl.Inst. Ophthalmol.2025;8(2): 63-68
Author: Murtuza Nuruddin
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7236666136
